Recent Updates — CRVO

CervoMed Inc. announced that its drug candidate neflamapimod has been granted an Innovation Passport to enter the UK’s Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB). This designation, awarded on August 4, 2026, provides early coordination with UK regulators and health technology assessment bodies to potentially accelerate market access. The company is currently seeking a strategic partner to advance neflamapimod into a Phase 3 trial for DLB. CervoMed Inc. operates in the biotechnology industry, developing treatments for age-related brain disorders.

CervoMed Inc. announced clinical, plasma biomarker, and imaging data for its lead drug candidate, neflamapimod, in treating dementia with Lewy bodies, which was presented at the Alzheimer's Association International Conference 2026. CervoMed Inc. is a biotechnology company focused on developing therapeutic solutions for neurodegenerative diseases.

CervoMed Inc. announced on July 9, 2026, that it has completed enrollment in its Phase 2a clinical study of neflamapimod for treating nonfluent variant primary progressive aphasia, a form of frontotemporal dementia. CervoMed Inc. is a biotechnology company focused on developing therapeutic solutions for neurodegenerative diseases.

CervoMed Inc. closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share. CervoMed Inc. is a biotechnology company focused on developing medical devices and therapies for treating inflammatory and inflammatory-related diseases.